Innovimmune to Present Superior Preclinical Therapeutic Efficacy Results in Rheumatoid Arthritis of Its INV-17 ROR Gamma t Inhibitor Program at the 2014 American College of Rheumatology Annual Meeting NEW YORK, Nov. 5, 2014 (GLOBE NEWSWIRE) -- Specialty drug discovery company, Innovimmune Biotherapeutics Holding, LLC will present data demonstrating successful treatment of rheumatoid arthritis [RA]...

Innovimmune's Preclinical Data on Highly Selective ROR Gamma Inhibitor Prevents Multiple Sclerosis in Mice NEW YORK, Jan. 15, 2014 (GLOBE NEWSWIRE) -- Specialty drug discovery company, Innovimmune Biotherapeutics Holding, LLC presented data at the XXI World Congress of Neurology in Vienna, Austria...